首页> 外文期刊>Journal of clinical laboratory analysis. >Carbamoyl phosphate synthetase 1 deficiency diagnosed by whole exome sequencing
【24h】

Carbamoyl phosphate synthetase 1 deficiency diagnosed by whole exome sequencing

机译:通过全外显子组测序诊断出氨甲酰磷酸合成酶1缺乏症

获取原文
获取外文期刊封面目录资料

摘要

BackgroundCarbamoyl Phosphate Synthetase 1 deficiency (CPS1D) is a rare autosomal recessive inborn metabolic disease characterized mainly by hyperammonemia. The fatal nature of CPS1D and its similar symptoms with other urea cycle disorders (UCDs) make its diagnosis difficult, and the molecular diagnosis is hindered due to the large size of the causative gene CPS1 . Therefore, the objective of the present study was to investigate the clinical applicability of exome sequencing in molecular diagnosis of CPS1D in Chinese population. MethodsWe described two Chinese neonates presented with unconsciousness and drowsiness due to deepening encephalopathy with hyperammonemia. Whole exome sequencing was performed. Candidate mutations were validated by Sanger sequencing. In-silicon analysis was processed for the pathogenicity predictions of the identified mutations. ResultsTwo compound heterozygous mutations in the gene carbamoyl phosphate synthetase 1( CPS1) were identified. One is in Case 1 with two novel missense mutations (c.2537CT, p. Pro846Leu and c.3443TA, p.Met1148Lys), and the other one is in Case 2 with a novel missense mutation (c.1799GA, p.Cys600Tyr) and a previously reported 12-bp deletion (c.4088_4099del, p.Leu 1363_Ile1366del). Bioinformatics deleterious predictions indicated pathogenicity of the missense mutations. Conversation analysis and homology modeling showed that the substituted amino acids were highly evolutionary conserved and necessary for enzyme stability or function. ConclusionThe present study initially and successfully applied whole exome sequencing to the molecular diagnosis of CPS1D in Chinese neonates, indicating its applicability in cost-effective molecular diagnosis of CPS1D. Three novel pathogenic missense mutations were identified, expanded the mutational spectrum of the CPS1 gene.
机译:背景氨基甲酸酯磷酸合成酶1缺乏症(CPS1D)是一种罕见的常染色体隐性遗传性先天性代谢疾病,主要特征为高氨血症。 CPS1D的致命性质以及与其他尿素循环系统疾病(UCDs)相似的症状使其难以诊断,并且由于致病基因CPS1的大小,阻碍了分子诊断。因此,本研究的目的是研究外显子组测序在中国人群CPS1D分子诊断中的临床适用性。方法我们描述了两名因高氨血症加深脑病而出现昏迷和嗜睡的中国新生儿。进行了整个外显子组测序。通过Sanger测序验证候选突变。进行了硅内分析,用于确定突变的致病性预测。结果鉴定出氨基甲酰磷酸合成酶1(CPS1)基因的两个复合杂合突变。一种是在案例1中出现两个新的错义突变(c.2537C> T,p.Pro846Leu和c.3443T> A,p.Met1148Lys),另一种是在案例2中发生一个新的错义突变(c.1799G> A,p.Cys600Tyr)和先前报道的12bp缺失(c.4088_4099del,p.Leu 1363_Ile1366del)。生物信息学的有害预测表明了错义突变的致病性。会话分析和同源性建模表明,取代的氨基酸是高度进化保守的,是酶稳定性或功能所必需的。结论本研究初步成功地将全外显子组测序应用于中国新生儿CPS1D的分子诊断,表明其可用于经济有效的CPS1D分子诊断。确定了三个新的致病性错义突变,扩大了CPS1基因的突变谱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号